KR102677442B1 - 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법 - Google Patents

케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법 Download PDF

Info

Publication number
KR102677442B1
KR102677442B1 KR1020207011664A KR20207011664A KR102677442B1 KR 102677442 B1 KR102677442 B1 KR 102677442B1 KR 1020207011664 A KR1020207011664 A KR 1020207011664A KR 20207011664 A KR20207011664 A KR 20207011664A KR 102677442 B1 KR102677442 B1 KR 102677442B1
Authority
KR
South Korea
Prior art keywords
inhibitor
alkyl
ccr2
cancer
chemokine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207011664A
Other languages
English (en)
Korean (ko)
Other versions
KR20200110300A (ko
Inventor
제임스 제이. 캠벨
전화 미아오
토마스 제이. 샬
이스라엘 샤로
시지에 리
크리스틴 마리 잔손
라진더 싱
카렌 엡스워스
Original Assignee
케모센트릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케모센트릭스, 인크. filed Critical 케모센트릭스, 인크.
Publication of KR20200110300A publication Critical patent/KR20200110300A/ko
Application granted granted Critical
Publication of KR102677442B1 publication Critical patent/KR102677442B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207011664A 2017-09-25 2018-09-24 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법 Active KR102677442B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562952P 2017-09-25 2017-09-25
US62/562,952 2017-09-25
PCT/US2018/052408 WO2019060820A1 (en) 2017-09-25 2018-09-24 POLYTHERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR

Publications (2)

Publication Number Publication Date
KR20200110300A KR20200110300A (ko) 2020-09-23
KR102677442B1 true KR102677442B1 (ko) 2024-06-20

Family

ID=65810578

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011664A Active KR102677442B1 (ko) 2017-09-25 2018-09-24 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법

Country Status (16)

Country Link
US (1) US11304952B2 (https=)
EP (1) EP3687525B1 (https=)
JP (2) JP7453139B2 (https=)
KR (1) KR102677442B1 (https=)
CN (2) CN118267479A (https=)
AR (1) AR112831A1 (https=)
AU (2) AU2018335486B8 (https=)
BR (1) BR112020005284A2 (https=)
CA (2) CA3293051A1 (https=)
ES (1) ES3058135T3 (https=)
IL (1) IL273188B2 (https=)
MA (1) MA50665A (https=)
MX (1) MX2020003192A (https=)
SG (1) SG11202002119QA (https=)
TW (1) TWI875682B (https=)
WO (1) WO2019060820A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2904252T3 (es) 2015-05-21 2022-04-04 Chemocentryx Inc Moduladores de CCR2
US20190275015A1 (en) * 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
IL275898B2 (en) * 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
JP7387616B2 (ja) 2018-02-22 2023-11-28 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン
AU2020276277B2 (en) 2019-05-15 2025-03-20 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
CN114555080B (zh) 2019-10-16 2025-10-10 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯胺
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187393A1 (en) * 2015-05-21 2016-11-24 Chemocentryx, Inc. Ccr2 modulators

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
CA2049973C (en) 1990-02-28 2002-12-24 Rodney G. Wolff Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AR034257A1 (es) 2000-06-30 2004-02-18 Du Pont Pharm Co Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas
EP1318811B1 (en) 2000-08-17 2006-08-30 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
KR20040013090A (ko) 2001-07-02 2004-02-11 아스트라제네카 아베 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
US20060030582A1 (en) 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JP4459807B2 (ja) 2002-04-29 2010-04-28 メルク エンド カムパニー インコーポレーテッド テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤
EP1501507B1 (en) 2002-04-29 2008-05-28 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2004041777A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Heteroarylpiperidine modulators of chemokine receptor activity
US7557120B2 (en) 2003-02-24 2009-07-07 Merck & Co., Inc. Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
WO2004082682A1 (en) 2003-03-18 2004-09-30 Merck & Co. Inc. Amino cyclobutylamide modulators of chemokine receptor activity
KR20060003353A (ko) 2003-04-15 2006-01-10 머크 앤드 캄파니 인코포레이티드 케모킨 수용체의벤족사지닐-아미도사이클로펜틸-헤테로사이클릭 조절제
CA2521625A1 (en) 2003-04-17 2004-11-04 Merck & Co., Inc. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
ATE517622T1 (de) 2003-10-27 2011-08-15 Merck Sharp & Dohme Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
EP1701724A4 (en) 2004-01-02 2007-11-14 Merck & Co Inc ALKYLAMINO, ARYLAMINO AND SULFONAMIDOCYCLOPENTYLAMIDE MODULATORS OF THE ACTIVITY OF CHEMOKIN RECEPTORS
CA2555073A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Amino heterocyclic modulators of chemokine receptor activity
JP2007537264A (ja) 2004-05-11 2007-12-20 インサイト コーポレイション ケモカインレセプタのモジュレータとしての３−（４−ヘテロアリールシクロヘキシルアミノ）シクロペンタンカルボキサミド
UY29219A1 (es) 2004-11-22 2006-04-28 Incyte Corp Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
CN101098700A (zh) 2005-01-06 2008-01-02 默克公司 治疗炎性疾病的药物组合疗法和药用组合物
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
PL2175859T3 (pl) 2007-07-12 2012-09-28 Chemocentryx Inc Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
WO2010068663A1 (en) 2008-12-10 2010-06-17 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
MX2011010919A (es) 2009-04-16 2011-11-02 Janssen Pharmaceutica Nv Antagonistas del receptor 2 de citocina quimioatrayente de 4-azetidinil-1-heteroaril-ciclohexano.
CN102459227B (zh) 2009-04-17 2014-08-20 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
US9040526B2 (en) 2010-02-09 2015-05-26 Bristol-Myers Squibb Company Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
TW201204717A (en) 2010-06-17 2012-02-01 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
AU2012226890B2 (en) 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
CA2920113A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TN2017000084A1 (en) 2014-09-11 2018-07-04 Bristol Myers Squibb Co Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
WO2017165125A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
US12134654B2 (en) * 2017-04-19 2024-11-05 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
US20190275015A1 (en) 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
JP2021511344A (ja) 2018-01-22 2021-05-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌を治療する組成物および方法
US20200297708A1 (en) 2019-03-19 2020-09-24 Chemocentryx, Inc. Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187393A1 (en) * 2015-05-21 2016-11-24 Chemocentryx, Inc. Ccr2 modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Immunology Research, Abstract A107, 2016.

Also Published As

Publication number Publication date
AU2018335486A1 (en) 2020-03-26
CN111712242B (zh) 2023-11-24
BR112020005284A2 (pt) 2020-09-24
MA50665A (fr) 2020-08-05
RU2020112755A3 (https=) 2022-03-31
AU2018335486A8 (en) 2024-12-05
AU2018335486B2 (en) 2024-07-04
CN111712242A (zh) 2020-09-25
AU2018335486B8 (en) 2024-12-05
US11304952B2 (en) 2022-04-19
EP3687525B1 (en) 2025-10-29
CA3075638A1 (en) 2019-03-28
TW201922287A (zh) 2019-06-16
WO2019060820A1 (en) 2019-03-28
RU2020112755A (ru) 2021-10-28
CN118267479A (zh) 2024-07-02
MX2020003192A (es) 2020-07-29
IL273188B (en) 2022-11-01
ES3058135T3 (en) 2026-03-09
IL273188A (en) 2020-04-30
IL273188B2 (en) 2023-03-01
SG11202002119QA (en) 2020-04-29
EP3687525A4 (en) 2021-10-13
US20190134049A1 (en) 2019-05-09
EP3687525A1 (en) 2020-08-05
JP2023181168A (ja) 2023-12-21
JP2020535144A (ja) 2020-12-03
CA3293051A1 (en) 2026-03-02
AR112831A1 (es) 2019-12-18
TWI875682B (zh) 2025-03-11
AU2024204212A1 (en) 2024-07-11
JP7453139B2 (ja) 2024-03-19
US20230023075A1 (en) 2023-01-26
AU2024204212B2 (en) 2025-12-18
KR20200110300A (ko) 2020-09-23

Similar Documents

Publication Publication Date Title
KR102677442B1 (ko) 케모카인 수용체 2(ccr2) 길항제 및 pd-1/pd-l1 억제제를 사용하는 병용 요법
JP7611189B2 (ja) Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
US20240285593A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
US12611409B2 (en) Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
RU2796863C2 (ru) Комбинированная терапия с использованием антагониста хемокинового рецептора 2 (CCR2) и ингибитора PD-1/PD-L1
EP3941467A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
CA3019391C (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK40004572B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601